Abstract
Migraine is a global disorder and considerably affecting people`s quality of life. Treatments include nonsteroidal anti-inflammatory drugs-containing medicinal products among whom acetylsalicylic acid-containing Aspirin® has been proven effectively to relief migraine headache. Early treatment is recommended for patients with migraine attacks. A requirement for early onset of action includes tablet disintegration and consequent active ingredient dissolution and absorption. The bioavailability of a new quickly disintegrating 1,000 mg aspirin formulation has been investigated in a bioequivalence study versus a marketed Aspirin® formulation with clinically demonstrated early onset of action. The new formulation has a tablet strength (1,000 mg) and time to maximum plasma concentration (mean 21.6 minutes) providing upside for people requiring treatment of migraine headache
Highlights
The burden of migraine is considerable, as it affects 11% of people globally and significantly diminishes the quality of life and normal functioning of most sufferers [1]
The bioavailability of a new quickly disintegrating 1,000 mg aspirin formulation has been investigated in a bioequivalence study versus a marketed Aspirin® formulation with clinically demonstrated early onset of action
The role of non-prescription medicinal product treatment options for acute migraine episodes is large, as a majority of patients opt for self-treatment over medical consultation with a physician [2]
Summary
The burden of migraine is considerable, as it affects 11% of people globally and significantly diminishes the quality of life and normal functioning of most sufferers [1]. Aspirin (acetylsalicylic acid, ASA) in doses of 1,000 mg has been proven to effectively relief migraine headache [3,4,5,6,7,8,9,10,11,12,13]. A rapid onset of action is desirable for relief of acute pain in general, but holds even more weight in the case of migraine headache. In this context, timing of relief may have clinical relevance. Research has suggested a link between adequate treatment early in the course of migraine attack, while headache pain is still mild, and better outcomes [14,15,16,17,18]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
